TABLE 2.
Total number of AEs by arm and overall for patients with metastatic colorectal cancer receiving FOLFOX or CUFOX treatment1
| FOLFOX | CUFOX | Total | |
|---|---|---|---|
| Constipation | 4 (3.9) | 7 (2.5) | 11 (2.9) |
| Diarrhea | 6 (5.8) | 12 (4.3) | 18 (4.7) |
| Dyspepsia | 4 (3.9) | 10 (3.6) | 14 (3.6) |
| Fatigue | 8 (7.8) | 26 (9.2) | 34 (8.8) |
| Nausea | 5 (4.9) | 8 (2.8) | 13 (3.4) |
| Oral mucositis | 5 (4.9) | 10 (3.6) | 15 (3.9) |
| Peripheral sensory neuropathy | 6 (5.8) | 25 (8.9) | 31 (8.1) |
| Platelet count decreased | 4 (3.9) | 13 (4.6) | 17 (4.4) |
1
Values are n (%) of all AEs in each arm and overall for the intention-to-treat population, reported for those events that constituted ≥2.5% of all AEs. Number of patients on FOLFOX and CUFOX was 9 and 18, respectively. AE, adverse event; CUFOX, folinic acid/5-fluorouracil/oxaliplatin + 2 g oral curcumin/d; FOLFOX, folinic acid/5-fluorouracil/oxaliplatin.